Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

21. Glutamate neurometabolites in treatment resistant schizophrenia: a meta analysis of 1H-MRS studies

Glutamate neurometabolites in treatment resistant schizophrenia: a meta analysis of 1H-MRS studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

22. Physical exercise for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials

Physical exercise for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

23. Depression and schizophrenia: a systematic review and meta-analysis

Depression and schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

24. Health state utility values in patients with schizophrenia: a systematic review and meta-analysis

Health state utility values in patients with schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

25. Impact of smoking on cognitive function in patients with schizophrenia: a meta-analysis

Impact of smoking on cognitive function in patients with schizophrenia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

26. Mind-body therapies for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials

Mind-body therapies for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

27. Humour-based interventions for people with schizophrenia [Cochrane protocol]

Humour-based interventions for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

28. Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms [Cochrane protocol]

Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

29. Clinical predictors of poor response to clozapine in schizophrenia: a systematic review

Clinical predictors of poor response to clozapine in schizophrenia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

30. Co-occurrence of hallucinations and delusions in schizophrenia spectrum and related disorders: a systematic review

Co-occurrence of hallucinations and delusions in schizophrenia spectrum and related disorders: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

31. Systematic review of non-biomedical interventions for relapse prevention in people with schizophrenia

Systematic review of non-biomedical interventions for relapse prevention in people with schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

32. Comparison of the efficacy and safety of aripiprazole and brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Comparison of the efficacy and safety of aripiprazole and brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

33. Comparative ef?cacy and acceptability of antibiotics and pre/probiotics as add-on treatment for schizophrenia: protocol for a network meta-analysis

Comparative ef?cacy and acceptability of antibiotics and pre/probiotics as add-on treatment for schizophrenia: protocol for a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

34. Cognitive performance in treatment resistant schizophrenia: a systematic review

Cognitive performance in treatment resistant schizophrenia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

35. Clozapine versus risperidone for people with schizophrenia [Cochrane protocol]

Clozapine versus risperidone for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

36. Clozapine versus quetiapine for people with schizophrenia [Cochrane protocol]

Clozapine versus quetiapine for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

37. Clozapine versus olanzapine for people with schizophrenia [Cochrane protocol]

Clozapine versus olanzapine for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

38. Clozapine (generic versus branded) for people with schizophrenia [Cochrane protocol]

Clozapine (generic versus branded) for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

39. Drop outs in non-pharmacological interventions in individuals at risk of psychosis versus patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials

Drop outs in non-pharmacological interventions in individuals at risk of psychosis versus patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

40. Efficacy of adjunctive D-Cycloserine for treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials

Efficacy of adjunctive D-Cycloserine for treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO